The bidirectional relationship between body mass index and treatment outcome in adolescents with treatment-resistant depression

Brandon Mansoor, Manivel Rengasamy, Robert Hilton, Giovanna Porta, Jiayan He, Anthony Spirito, Graham J. Emslie, Taryn L. Mayes, Gregory Clarke, Karen Wagner, Wael Shamseddeen, Boris Birmaher, Neal Ryan, David Brent

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective: Depression and obesity are associated, but the impact of obesity on depression treatment outcome, or, conversely, the impact of treatment on body mass index (BMI) in depressed adolescents has not been reported. In this article, we examine the bidirectional relationships between BMI and treatment response in adolescents with treatment-resistant depression. Method: Participants in the Treatment of Selective Serotonin Reuptake Inhibitor (SSRI) Resistant Depression in Adolescents (TORDIA) study had height and weight assessed at baseline, weekly for the first 6 weeks, biweekly for the next 6 weeks, and monthly from weeks 12 through 24. The impact of baseline BMI as a predictor and moderator of treatment response was assessed. In addition, participants' changes in BMI were assessed as a function of specific treatment assignment and treatment response. Results: Participants assigned to SSRIs had a greater increase in BMI-for-age-sex z-score and weight than did those assigned to venlafaxine. Post-hoc, those treated with paroxetine or citalopram had the biggest increases in BMI, relative to fluoxetine or venlafaxine. Overweight or obesity was neither a predictor nor a moderator of treatment outcome, nor of subsequent BMI change. Conclusions: Overweight status does not appear to affect treatment response in adolescents with resistant depression. The successful treatment of depression does not appear to favorably affect weight or BMI. Fluoxetine and venlafaxine are less likely to cause an increase in BMI than paroxetine or citalopram.

Original languageEnglish (US)
Pages (from-to)458-467
Number of pages10
JournalJournal of Child and Adolescent Psychopharmacology
Volume23
Issue number7
DOIs
StatePublished - Sep 1 2013

Fingerprint

Treatment-Resistant Depressive Disorder
Body Mass Index
Depression
Paroxetine
Citalopram
Obesity
Fluoxetine
Therapeutics
Weights and Measures
Serotonin Uptake Inhibitors

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health

Cite this

The bidirectional relationship between body mass index and treatment outcome in adolescents with treatment-resistant depression. / Mansoor, Brandon; Rengasamy, Manivel; Hilton, Robert; Porta, Giovanna; He, Jiayan; Spirito, Anthony; Emslie, Graham J.; Mayes, Taryn L.; Clarke, Gregory; Wagner, Karen; Shamseddeen, Wael; Birmaher, Boris; Ryan, Neal; Brent, David.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 23, No. 7, 01.09.2013, p. 458-467.

Research output: Contribution to journalArticle

Mansoor, B, Rengasamy, M, Hilton, R, Porta, G, He, J, Spirito, A, Emslie, GJ, Mayes, TL, Clarke, G, Wagner, K, Shamseddeen, W, Birmaher, B, Ryan, N & Brent, D 2013, 'The bidirectional relationship between body mass index and treatment outcome in adolescents with treatment-resistant depression', Journal of Child and Adolescent Psychopharmacology, vol. 23, no. 7, pp. 458-467. https://doi.org/10.1089/cap.2012.0095
Mansoor, Brandon ; Rengasamy, Manivel ; Hilton, Robert ; Porta, Giovanna ; He, Jiayan ; Spirito, Anthony ; Emslie, Graham J. ; Mayes, Taryn L. ; Clarke, Gregory ; Wagner, Karen ; Shamseddeen, Wael ; Birmaher, Boris ; Ryan, Neal ; Brent, David. / The bidirectional relationship between body mass index and treatment outcome in adolescents with treatment-resistant depression. In: Journal of Child and Adolescent Psychopharmacology. 2013 ; Vol. 23, No. 7. pp. 458-467.
@article{82d01866138c4bcab15fbd52528a80ac,
title = "The bidirectional relationship between body mass index and treatment outcome in adolescents with treatment-resistant depression",
abstract = "Objective: Depression and obesity are associated, but the impact of obesity on depression treatment outcome, or, conversely, the impact of treatment on body mass index (BMI) in depressed adolescents has not been reported. In this article, we examine the bidirectional relationships between BMI and treatment response in adolescents with treatment-resistant depression. Method: Participants in the Treatment of Selective Serotonin Reuptake Inhibitor (SSRI) Resistant Depression in Adolescents (TORDIA) study had height and weight assessed at baseline, weekly for the first 6 weeks, biweekly for the next 6 weeks, and monthly from weeks 12 through 24. The impact of baseline BMI as a predictor and moderator of treatment response was assessed. In addition, participants' changes in BMI were assessed as a function of specific treatment assignment and treatment response. Results: Participants assigned to SSRIs had a greater increase in BMI-for-age-sex z-score and weight than did those assigned to venlafaxine. Post-hoc, those treated with paroxetine or citalopram had the biggest increases in BMI, relative to fluoxetine or venlafaxine. Overweight or obesity was neither a predictor nor a moderator of treatment outcome, nor of subsequent BMI change. Conclusions: Overweight status does not appear to affect treatment response in adolescents with resistant depression. The successful treatment of depression does not appear to favorably affect weight or BMI. Fluoxetine and venlafaxine are less likely to cause an increase in BMI than paroxetine or citalopram.",
author = "Brandon Mansoor and Manivel Rengasamy and Robert Hilton and Giovanna Porta and Jiayan He and Anthony Spirito and Emslie, {Graham J.} and Mayes, {Taryn L.} and Gregory Clarke and Karen Wagner and Wael Shamseddeen and Boris Birmaher and Neal Ryan and David Brent",
year = "2013",
month = "9",
day = "1",
doi = "10.1089/cap.2012.0095",
language = "English (US)",
volume = "23",
pages = "458--467",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "7",

}

TY - JOUR

T1 - The bidirectional relationship between body mass index and treatment outcome in adolescents with treatment-resistant depression

AU - Mansoor, Brandon

AU - Rengasamy, Manivel

AU - Hilton, Robert

AU - Porta, Giovanna

AU - He, Jiayan

AU - Spirito, Anthony

AU - Emslie, Graham J.

AU - Mayes, Taryn L.

AU - Clarke, Gregory

AU - Wagner, Karen

AU - Shamseddeen, Wael

AU - Birmaher, Boris

AU - Ryan, Neal

AU - Brent, David

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Objective: Depression and obesity are associated, but the impact of obesity on depression treatment outcome, or, conversely, the impact of treatment on body mass index (BMI) in depressed adolescents has not been reported. In this article, we examine the bidirectional relationships between BMI and treatment response in adolescents with treatment-resistant depression. Method: Participants in the Treatment of Selective Serotonin Reuptake Inhibitor (SSRI) Resistant Depression in Adolescents (TORDIA) study had height and weight assessed at baseline, weekly for the first 6 weeks, biweekly for the next 6 weeks, and monthly from weeks 12 through 24. The impact of baseline BMI as a predictor and moderator of treatment response was assessed. In addition, participants' changes in BMI were assessed as a function of specific treatment assignment and treatment response. Results: Participants assigned to SSRIs had a greater increase in BMI-for-age-sex z-score and weight than did those assigned to venlafaxine. Post-hoc, those treated with paroxetine or citalopram had the biggest increases in BMI, relative to fluoxetine or venlafaxine. Overweight or obesity was neither a predictor nor a moderator of treatment outcome, nor of subsequent BMI change. Conclusions: Overweight status does not appear to affect treatment response in adolescents with resistant depression. The successful treatment of depression does not appear to favorably affect weight or BMI. Fluoxetine and venlafaxine are less likely to cause an increase in BMI than paroxetine or citalopram.

AB - Objective: Depression and obesity are associated, but the impact of obesity on depression treatment outcome, or, conversely, the impact of treatment on body mass index (BMI) in depressed adolescents has not been reported. In this article, we examine the bidirectional relationships between BMI and treatment response in adolescents with treatment-resistant depression. Method: Participants in the Treatment of Selective Serotonin Reuptake Inhibitor (SSRI) Resistant Depression in Adolescents (TORDIA) study had height and weight assessed at baseline, weekly for the first 6 weeks, biweekly for the next 6 weeks, and monthly from weeks 12 through 24. The impact of baseline BMI as a predictor and moderator of treatment response was assessed. In addition, participants' changes in BMI were assessed as a function of specific treatment assignment and treatment response. Results: Participants assigned to SSRIs had a greater increase in BMI-for-age-sex z-score and weight than did those assigned to venlafaxine. Post-hoc, those treated with paroxetine or citalopram had the biggest increases in BMI, relative to fluoxetine or venlafaxine. Overweight or obesity was neither a predictor nor a moderator of treatment outcome, nor of subsequent BMI change. Conclusions: Overweight status does not appear to affect treatment response in adolescents with resistant depression. The successful treatment of depression does not appear to favorably affect weight or BMI. Fluoxetine and venlafaxine are less likely to cause an increase in BMI than paroxetine or citalopram.

UR - http://www.scopus.com/inward/record.url?scp=84884513254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884513254&partnerID=8YFLogxK

U2 - 10.1089/cap.2012.0095

DO - 10.1089/cap.2012.0095

M3 - Article

C2 - 24024532

AN - SCOPUS:84884513254

VL - 23

SP - 458

EP - 467

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 7

ER -